Petra Pharma   Report issue

For profit Phase 2
Founded: New York NY United States (2016)
Status: Defunct (2021)

Organization Overview

First Clinical Trial
2019
NCT04073680
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Petra Pharma

Active Ingredients

Drugs in Phase 2 Trials (2)

canagliflozin (invokana) (1 trial)

serabelisib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Endometrial Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2